Glenmark Life Sciences Ltd Financials
Company Logo

Glenmark Life Sciences Ltd Financial Statement

Glenmark Life Sciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue594.11
Operating Expense429.13
Net Profit111.48
Net Profit Margin18.76
Earning Per Share9.10
EBIDTA163.74
Effective Tax Rate22.74

Glenmark Life Sciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual2,283.21
Operating Expenses Annual1,608.97
Operating Profit Annual686.29
Interest Annual1.55
Depreciation53.45
Net Profit Annual470.89
Tax Annual160.40

Glenmark Life Sciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning283.82
Cash Flow from Operations413.52
Cash Flow from Investing-116.48
Cash Flow from Financing-279.44
Cash Flow at the End301.41

Glenmark Life Sciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)30.06
PBIT Margin (%)27.72
PBT Margin (%)9.84
Net PROFIT Margin (%)20.62
Return On Networth / Equity (%)21.07
Return On Networth /Employed (%)27.94
Return On Assets (%)20.83
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)1.01

Glenmark Life Sciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual809.87
Total Current Assets Annual1,916.00
Non Current Assets Annual934.41
Total Shareholders Funds Annual2,332.32
Total Assets Annual2,850.41

Glenmark Life Sciences Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Oct 15, 2024, Glenmark Life Sciences Ltd has a market capitalization of 9,499.53 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Glenmark Life Sciences Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Glenmark Life Sciences Ltd recorded a total revenue of approximately 2,283.21 Cr marking a significant milestone in the company's financial performance.
Glenmark Life Sciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.0% annually, respectively..
Glenmark Life Sciences Ltd's current PE ratio is 20.17.
Glenmark Life Sciences Ltd's ROCE averaged 28.3% from the FY ending March 2022 to 2024, with a median of 28.8%. It peaked at 29.2% in March 2023, reflecting strong capital efficiency over the period..
Glenmark Life Sciences Ltd's latest EBIT is Rs. 632.84 Cr, surpassing the average EBIT of Rs. 618.30 Cr over the 5 years..